OPTIMISATION OF MOLECULAR ASSAYS FOR CLINICAL TRIAL OF GL67A/PDNA DELIVERY TO NOSE AND LUNG OF CF PATIENTS
主要な著者: | Sumner-Jones, S, McCormick, D, Coles, R, Pringle, I, McLachlan, G, Collie, D, Vrettou, C, Davies, J, Alton, E, Gill, DR, Hyde, S |
---|---|
フォーマット: | Journal article |
出版事項: |
2009
|
類似資料
-
3-STEP TAQMAN RT-PCR: ULTIMATE MESSENGER RNA DETECTION SENSITIVITY FOR CF GENE THERAPY CLINICAL TRIALS
著者:: McCormick, D, 等
出版事項: (2009) -
Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes.
著者:: Davies, L, 等
出版事項: (2008) -
EVALUATION OF SAFETY AND GENE EXPRESSION WITH A SINGLE DOSE OF PGM169/GL67A ADMINISTERED TO THE NOSE AND LUNG OF INDIVIDUALS WITH CF: THE UK CF GENE THERAPY CONSORTIUM "PILOT STUDY"
著者:: Davies, J, 等
出版事項: (2009) -
REPEAT ADMINISTRATION OF GL67A/PGM169 IS FEASIBLE, SAFE, AND PRODUCES ENDOGENOUS LEVELS OF CFTR EXPRESSION AFTER 12 DOSES
著者:: Alton, E, 等
出版事項: (2012) -
Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
著者:: Alton, E, 等
出版事項: (2012)